ProfileGDS5678 / 1422474_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 93% 92% 93% 93% 89% 87% 87% 87% 94% 97% 95% 96% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8436593
GSM967853U87-EV human glioblastoma xenograft - Control 27.8120693
GSM967854U87-EV human glioblastoma xenograft - Control 37.639692
GSM967855U87-EV human glioblastoma xenograft - Control 47.9871293
GSM967856U87-EV human glioblastoma xenograft - Control 57.962893
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7541489
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5011387
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6869487
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6418787
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.2950294
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.2174197
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.6548195
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.7532996
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.5048895